Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports

Gynecol Oncol. 2000 Jan;76(1):126-7. doi: 10.1006/gyno.1999.5641.

Abstract

Objective: We hereby report on two patients receiving goserelin due to breast cancer in whom a failure in ovarian ablation was detected. A review of the hormonal effects of LHRH analogues is performed.

Case reports: CASE 1: A 36-year-old female was diagnosed with breast carcinoma and treated with surgery, chemotherapy, radiotherapy, and goserelin. A 16-week gestation was detected after 17 months of uninterrumpted hormonal therapy at ablative doses. CASE 2: A 41-year-old female was diagnosed with breast carcinoma and treated with surgery, chemotherapy, radiotherapy, and tamoxifen. Goserelin was substituted for tamoxifen due to bone metastases and, 2 years later, a failure in ovarian ablation was confirmed after the reappearance of the patient's menses.

Conclusions: Goserelin-induced ovarian ablation may fail after the use of appropriate doses of this drug. We suggest a possible mechanism of hormone resistance induced by the long-term administration of LHRH analogues. No fetal damage was detected after goserelin exposure in the first 4 months of gestation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / therapy*
  • Female
  • Goserelin / pharmacology
  • Goserelin / therapeutic use*
  • Humans
  • Menstrual Cycle / drug effects
  • Ovary / drug effects*
  • Pregnancy
  • Premenopause*

Substances

  • Antineoplastic Agents, Hormonal
  • Goserelin